Drug intelligence / Profile preview

NAL2522

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Intramuscular

Overview

NAL2522 is a long-acting microsphere injection formulation of risperidone, an atypical antipsychotic, developed by NAL Pharmaceutical Group. It functions as an antagonist at both dopamine D2 and serotonin 5-HT2A receptors. Designed for the treatment of schizophrenia and other central nervous system (CNS) disorders, NAL2522 utilizes a microsphere delivery system to provide sustained release of the active ingredient. This formulation aims to improve patient adherence and maintain stable therapeutic plasma levels compared to daily oral dosing. It is currently in the preclinical stage of development.

Other names: Risperidone Microsphere Injection

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on NAL2522.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL2522.

Explore the full profile